Side-by-side · Research reference
CortagenvsSemaglutide
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-MechanisticHUMAN-REVIEWED11/35 cited
BFDA-ApprovedFlagship15/53 cited
Cortagen
Bioregulatory Tetrapeptide · Khavinson-School
Injectable · Animal models
Semaglutide
GLP-1 RA · FDA-Approved
SQ · Abdomen / thigh / arm · Once weekly
01Mechanism of Action
Parameter
Cortagen
Semaglutide
Primary target
Cerebral cortex tissue — molecular targets under investigation
GLP-1 receptor (GLP-1R)WEGOVY (semaglutide) injection 2021
Pathway
Antioxidant pathway modulation — suppression of LPO cascade, reduction of protein oxidative modificationKozina 2007
GLP-1R agonism → ↑glucose-dependent insulin secretion, ↓glucagon, ↓gastric emptying, ↓appetite via hypothalamic centresWilding 2021
Downstream effect
Decreased lipid peroxidation products, reduced oxidative protein damage, altered gene expression in cardiac tissueKozina 2007Anisimov 2004
Improved glycemic control, reduced caloric intake, body-weight reduction, cardiovascular risk reductionWilding 2021
Feedback intact?
—
Glucose-dependent insulin release preserves physiological feedback
Origin
Synthetic tetrapeptide derived from amino acid analysis of natural brain cortex peptide preparation CortexinAnisimov 2004
Modified GLP-1(7-37) with two amino-acid substitutions and C-18 fatty-acid acylation for albumin binding and 168-h half-lifeWEGOVY (semaglutide) injection 2021
Antibody development
—
—
02Dosage Protocols
Parameter
Cortagen
Semaglutide
Animal model dose (rat)
Injection protocol (dose not specified in abstracts)
Multiple injections over study period.
—
Avian model dose (chicken)
40-day injection courseKuznik 2008
Compared to epithalon in hypophysectomized and aged birds.
—
Human peripheral nerve study
Therapeutic course (protocol details not provided)
Posttraumatic recovery context — reference cited but not detailed.
—
Evidence basis
Animal mechanistic studies
FDA-approved · Phase 3 RCTsWilding 2021WEGOVY (semaglutide) injection 2021
Route
Injectable (inferred from animal protocols)
—
Standard dose (weight, Wegovy)
—
2.4 mg / week (after 16-wk titration)WEGOVY (semaglutide) injection 2021Wilding 2021
Frequency
—
Once weekly, same day each week
Titration schedule
—
0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg over 16 weeks
Mitigates GI side effects.
Duration
—
Indefinite for chronic indication
Discontinuation results in weight regain.
Reconstitution
—
Pre-mixed pen device (commercial). Research lyophilised vial: bacteriostatic water per label.
Timing
—
Any time of day, with or without food
04Side Effects & Safety
Parameter
Cortagen
Semaglutide
Antioxidant suppression
Suppression of antioxidant activity noted alongside LPO reductionKozina 2007
Mechanism unclear — possible homeostatic adaptation.
—
Immune/hemostasis effects
No effect on immunity or hemostasis parameters in avian hypophysectomy model (unlike epithalon)Kuznik 2008
Epithalon reversed deficits; cortagen did not.
—
Human safety data
No adverse events reported in peripheral nerve recovery context
Limited detail in available abstracts.
—
Injection site reaction
—
Mild erythema, pruritus
Thyroid C-cell tumours
—
Boxed warning — contraindicated in MEN2 / personal or family MTC historyWEGOVY (semaglutide) injection 2021
Hypoglycemia
—
Low risk as monotherapy; elevated when combined with sulfonylureas / insulin
Gallbladder events
—
Increased cholelithiasis
Heart rate
—
Modest ↑ resting HR (~2-4 bpm)
Absolute Contraindications
Cortagen
—Semaglutide
- ·Personal or family history of medullary thyroid carcinoma
- ·Multiple endocrine neoplasia syndrome type 2
- ·Pregnancy / breastfeeding
- ·Hypersensitivity to semaglutide
Relative Contraindications
Cortagen
—Semaglutide
- ·Severe gastroparesis
- ·History of pancreatitis
- ·Diabetic retinopathy (may worsen with rapid glycemic improvement)
05Administration Protocol
Parameter
Cortagen
Semaglutide
1. Preparation
Reconstitute lyophilised peptide with bacteriostatic water per supplier protocol. Exact volumes depend on concentration supplied.
Commercial: pre-filled pen, no reconstitution. Research vial: per-label or bacteriostatic water.
2. Injection site
Subcutaneous injection typical for bioregulatory peptides — abdomen or thigh. Rotate sites.
SQ — abdomen, thigh, or upper arm. Rotate sites weekly to avoid lipohypertrophy.
3. Timing
Animal protocols used repeated dosing over weeks. Human timing not established — evening administration common in Khavinson tradition.
Once weekly, same day. Day can be changed if ≥2 days separate doses.
4. Storage
Lyophilised: refrigerate or freeze per supplier. Reconstituted: refrigerate 2–8 °C, use within guideline window.
Pen: refrigerate 2–8 °C unopened; room temp ≤30 °C up to 56 days after first use.
5. Needle
—
Pen-supplied 31–34G needle. Research vial: 27–31G insulin syringe.
06Stack Synergy
Cortagen
— no documented stacks
Semaglutide
+ Tirzepatide
WeakCombining two GLP-1 RA-class drugs is not clinically validated and risks additive GI toxicity. Tirzepatide's GIP component already provides complementary mechanism vs pure GLP-1; stacking with semaglutide adds receptor saturation but no synergy. NOT recommended.
- Note
- Stack not recommended — choose one GLP-1 RA
- Primary benefit
- (none — additive toxicity, no synergy)